Krsnaa Diagnostics has debuted at Rs 1,025.00 on the BSE, up by 71.00 points or 7.44% from its issue price of Rs 954.
The scrip is currently trading at Rs 1,026.35, up by 72.35 points or 7.58% from its issue price. It has touched a high and low of Rs 1099.50 and Rs 961.45 respectively. So far 3.31 lakh shares were traded on the counter.
The offering which was opened for subscription between August 04, 2021 and August 06, 2021 was subscribed by qualified institutional buyers (QIBs) by 49.83 times, the non institutional investors (NII) were subscribed 116.30 times, and the retail portion was subscribed 41.95 times. The issue price was fixed at Rs 954 per share i.e. at upper end of price band of Rs 933-954 apiece.
Krsnaa Diagnostics is one of the fastest-growing diagnostic chains in India. The company offers a wide range of diagnostic services such as imaging/radiology services (X-rays, MRI, etc.), routine clinical laboratory tests, pathology, and tele-radiology services to private and public hospitals, medical colleges, and community health centres.
| Company Name | CMP |
|---|---|
| Apollo Hospital Ent. | 7699.05 |
| Max Healthcare Inst | 1006.90 |
| Narayana Hrudayalay | 1825.55 |
| Aster DM Healthcare | 688.30 |
| Global Health | 1089.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: